Categories: News

Ultimovacs ASA: Mandatory notification of trade by primary insider

Oslo, 17 February 2022, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at an average price of NOK 93.66 per share. Following this transaction, Carlos de Sousa and closely related parties hold 16,056 shares and 416,035 share options in Ultimovacs ASA.

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act.

 

Attachment

Staff

Recent Posts

Welldoc Partners with CLEAR to Integrate Secure Identity Verification in AI-Powered Cardiometabolic Health Platform

Collaboration Advances CMS Health Tech Ecosystem Goals by Enabling Seamless, Secure Access to Health Data…

2 hours ago

Both Ends Believing Celebrates 15 Years of Transforming Global Child Welfare Through Technology

DALLAS, Dec. 4, 2025 /PRNewswire/ -- Both Ends Believing (BEB), a Dallas-based global nonprofit with…

2 hours ago

Sage introduces skilled nursing solution to Sage Core, expanding its unified platform across all levels of senior care

Skilled brings wireless-first nurse call, real-time insights, and integrated workflows, completing Sage Core's support across…

2 hours ago

MJFF Initiates Funding for Emerging Therapeutic Targets in Parkinson’s Disease

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF)…

2 hours ago

Clinical Communication & Collaboration Market worth $5,302.9 million by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., Dec. 8, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the Clinical Communication & Collaboration…

2 hours ago

Dr. Shawn Griffin recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare

WASHINGTON, Dec. 8, 2025 /PRNewswire/ -- URAC is proud to announce that its President and CEO,…

2 hours ago